AccurKardia

Automated interpretation is the entire product. The system performs beat by beat analysis, detects ventricular and supraventricular ectopic beats, measures heart rate, and automatically interprets thirteen rhythm classifications including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company sells software rather than hardware and is device agnostic across patches, Holter monitors, and telemetry, so the algorithm is the whole of what is purchased.

The system produces fully automated interpretation intended to be reviewed within existing clinical workflows at cardiac monitoring companies, hospitals, and independent diagnostic testing facilities, rather than delivering a standalone diagnosis to a patient. The company has stated an explicit design commitment to explainable output rather than a black box approach, which is the mechanism that makes the physician review meaningful. Buyers should establish the over read requirements their accreditation and payer contracts impose, since the software's speed does not remove those obligations.

The regulatory pathway itself provides the transparency floor here, since a 510(k) submission requires performance data against a predicate, and two clearances mean two rounds of that. The company additionally states an explicit no black box position with explainable output, and publishes a stated 99 percent accuracy figure and a defined scope of thirteen rhythm classifications with an indicated population of adults aged 22 and older. Model architecture and training data provenance are not published.

Two FDA clearances constitute submitted performance evidence reviewed by a regulator, which is a materially higher bar than vendor assertion and is what distinguishes this from most AI in the index. Reported performance is 99 percent accuracy across the cleared rhythm classifications with results delivered in minutes rather than days. What is not published is peer reviewed prospective evaluation in deployed clinical settings or comparative accuracy against cardiologist over read, which is what would move this to an A.

No published PHI handling or data governance framework was located. The platform is cloud based and ingests ECG data from third party devices, so the data flow crosses organizational boundaries between device makers, monitoring companies, and interpreting facilities, which makes stewardship terms a question a buyer should resolve in contracting.

No HIPAA or BAA commitment was located in public materials. Given the customer set includes hospitals and independent diagnostic testing facilities, business associate arrangements almost certainly exist contractually, but nothing is published.

No SOC 2, HITRUST, or ISO 27001 attestation was located. Worth stating explicitly for buyers: FDA clearance evaluates safety and effectiveness of the device, not the vendor's information security posture, and the two should never be treated as substitutes.

The strongest regulatory position among the vendors added in this batch, and among the clearer ones in the index. The AccurECG Analysis System is an FDA cleared Class II Software as a Medical Device, and the platform has now secured two separate 510(k) clearances, the most recent being version 2.0 under K252361 in January 2026 with a specific cleared scope of thirteen rhythm classifications and an indicated population of adults 22 and older. Separately, the company reports FDA Breakthrough Device Designation for an investigational ECG based hyperkalemia risk assessment tool, which is a designation to expedite review rather than a clearance and should not be read as authorization for that pipeline product.

No governance framework or bias evaluation was located. The relevant question in automated ECG interpretation is performance variation across demographics, body habitus, lead placement quality, and device source, particularly for a platform that markets device agnostic ingestion; no published analysis addresses that variation.

Interoperability here means device rather than chart, and on that axis it is a design principle: the platform is explicitly device agnostic, ingesting data from patches, Holter monitors, event recorders, and telemetry devices without custom integration work, and is built for flexible customer integrations at enterprise scale. That matters commercially because it lets monitoring companies and OEMs adopt without re platforming. No EHR, HL7, or FHIR integration was located.

Described as a cloud based enterprise grade platform designed for scale and high ECG volumes with flexible customer integrations. Beyond the cloud characterization, no tenancy, hosting, or data residency terms are published.

No published pricing. The buyer set spans cardiac monitoring companies, device manufacturers, hospitals, and independent diagnostic testing facilities, and a volume based interpretation model would be typical for this category, but no rate or structure is disclosed.

Single modality and single specialty by design: cardiac rhythm interpretation from ECG, with a cleared scope of thirteen rhythm classifications in adults 22 and older. Settings span cardiac monitoring services, device makers, hospitals, and independent diagnostic testing facilities. The stated ambition to extend ECG into a broader diagnostic biomarker, evidenced by the hyperkalemia pipeline product, is roadmap rather than current capability.